Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Pediatric Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Hematology
How would you treat a pediatric patient with fully resected (stage I) nodular sclerosing Hodgkin lymphoma?
Related Questions
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
How do you decide between treatment with ABVD vs A + AVD in a patient in their 70s with advanced stage 4 classical Hodgkin lymphoma?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
Can Hodgkin-like PTLD be treated with Rituximab and weaning of immunosuppression, or is Hodgkin-directed chemotherapy necessary for cure?
Does the use of A+AVD versus ABVD affect your decision for consolidation RT for bulky Hodgkin lymphoma?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
